Limits...
Non-steroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia.

Barozzi N, Tett SE - BMC Health Serv Res (2008)

Bottom Line: This is important for medicines with issues around safety and quality of use, like non selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors.Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately 80 to 40 DDD/1000 beneficiaries/day).Despite initial divergence in celecoxib use between Queensland and Australia, the use of ns-NSAIDs, COX-2 inhibitors and paracetamol overall, in concession beneficiaries, was comparable in Australia and Queensland.

View Article: PubMed Central - HTML - PubMed

Affiliation: School of Pharmacy, University of Queensland, Steele Building, Brisbane, QLD 4072, Australia. nbarozzi@pharmacy.uq.edu.au

ABSTRACT

Background: Cross national drug utilization studies can provide information about different influences on physician prescribing. This is important for medicines with issues around safety and quality of use, like non selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors. To enable comparison of prescription medicine use across different jurisdictions with a range of population sizes, data first need to be compared within Australia to understand whether use in a smaller sub-population may be considered as representative of the total use within Australia. The aim of this study was to compare the utilization of non selective NSAID, COX-2 inhibitors and paracetamol between Queensland and Australia.

Method: Dispensing data were obtained for concession beneficiaries for Australia for ns-NSAIDs, COX-2 inhibitors and paracetamol subsidized by the PBS over the period 1997-2003. The same data were purchased for Queensland. Data were converted to Defined Daily Dose (DDD)/1000 beneficiaries/day (World Health Organization anatomical therapeutic chemical classification, 2005).

Results: Total NSAID and paracetamol consumption were similar in Australia and Queensland. Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately 80 to 40 DDD/1000 beneficiaries/day). Paracetamol was constant (approximately 45 DDD/1000 beneficiaries/day). COX-2 inhibitors consumption was initially higher in Queensland than in the whole of Australia.

Conclusion: Despite initial divergence in celecoxib use between Queensland and Australia, the use of ns-NSAIDs, COX-2 inhibitors and paracetamol overall, in concession beneficiaries, was comparable in Australia and Queensland.

Show MeSH

Related in: MedlinePlus

COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 2000 and 2003.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2562379&req=5

Figure 2: COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 2000 and 2003.

Mentions: In Figure 1, ns-NSAIDs and overall NSAIDs dispensing data for concession beneficiaries, over the period 1997–2003, in Australia and Queensland are shown. Ns-NSAID consumption in concession beneficiaries was similar in Australia and in Queensland. Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately 80 to 40 DDD/1000 concession beneficiaries/day) (Figure 1). COX-2 inhibitors uptake was high in the period 2000–2003. The overall use of COX-2 inhibitors started at about 60 and 40 DDD/1000 concession beneficiaries/day, respectively in Queensland and Australia, when celecoxib was introduced into Australia (2000). There was initial different use of COX-2 inhibitors: 55 DDD/1000 concession beneficiaries in Queensland vs 36 DDD/1000 concession beneficiaries in Australia (P = 0.46) (Figure 2). However, as the other COX-2 inhibitors (rofecoxib and meloxicam) came on to the market (2002), use rapidly became similar in Australia and in Queensland (approximately 45 DDD/1000 concession beneficiaries/day) (Figure 2).


Non-steroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia.

Barozzi N, Tett SE - BMC Health Serv Res (2008)

COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 2000 and 2003.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2562379&req=5

Figure 2: COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 2000 and 2003.
Mentions: In Figure 1, ns-NSAIDs and overall NSAIDs dispensing data for concession beneficiaries, over the period 1997–2003, in Australia and Queensland are shown. Ns-NSAID consumption in concession beneficiaries was similar in Australia and in Queensland. Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately 80 to 40 DDD/1000 concession beneficiaries/day) (Figure 1). COX-2 inhibitors uptake was high in the period 2000–2003. The overall use of COX-2 inhibitors started at about 60 and 40 DDD/1000 concession beneficiaries/day, respectively in Queensland and Australia, when celecoxib was introduced into Australia (2000). There was initial different use of COX-2 inhibitors: 55 DDD/1000 concession beneficiaries in Queensland vs 36 DDD/1000 concession beneficiaries in Australia (P = 0.46) (Figure 2). However, as the other COX-2 inhibitors (rofecoxib and meloxicam) came on to the market (2002), use rapidly became similar in Australia and in Queensland (approximately 45 DDD/1000 concession beneficiaries/day) (Figure 2).

Bottom Line: This is important for medicines with issues around safety and quality of use, like non selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors.Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately 80 to 40 DDD/1000 beneficiaries/day).Despite initial divergence in celecoxib use between Queensland and Australia, the use of ns-NSAIDs, COX-2 inhibitors and paracetamol overall, in concession beneficiaries, was comparable in Australia and Queensland.

View Article: PubMed Central - HTML - PubMed

Affiliation: School of Pharmacy, University of Queensland, Steele Building, Brisbane, QLD 4072, Australia. nbarozzi@pharmacy.uq.edu.au

ABSTRACT

Background: Cross national drug utilization studies can provide information about different influences on physician prescribing. This is important for medicines with issues around safety and quality of use, like non selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors. To enable comparison of prescription medicine use across different jurisdictions with a range of population sizes, data first need to be compared within Australia to understand whether use in a smaller sub-population may be considered as representative of the total use within Australia. The aim of this study was to compare the utilization of non selective NSAID, COX-2 inhibitors and paracetamol between Queensland and Australia.

Method: Dispensing data were obtained for concession beneficiaries for Australia for ns-NSAIDs, COX-2 inhibitors and paracetamol subsidized by the PBS over the period 1997-2003. The same data were purchased for Queensland. Data were converted to Defined Daily Dose (DDD)/1000 beneficiaries/day (World Health Organization anatomical therapeutic chemical classification, 2005).

Results: Total NSAID and paracetamol consumption were similar in Australia and Queensland. Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately 80 to 40 DDD/1000 beneficiaries/day). Paracetamol was constant (approximately 45 DDD/1000 beneficiaries/day). COX-2 inhibitors consumption was initially higher in Queensland than in the whole of Australia.

Conclusion: Despite initial divergence in celecoxib use between Queensland and Australia, the use of ns-NSAIDs, COX-2 inhibitors and paracetamol overall, in concession beneficiaries, was comparable in Australia and Queensland.

Show MeSH
Related in: MedlinePlus